

Enterome Receives FDA IND Clearance for EO2463, an 'OncoMimic' based Immunotherapy Targeting Liquid Tun

Phase1/2 clinical trials in patients with follicular lymphoma and marginal zone lymphoma expect Q2 2021

ENTEROME SA, a clinical stage biopharmaceutical company developing novel drugs based on its un de-code molecular interactions in the gut microbiome impacting human health, today announce received Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA) to a Phase 1/2 clinical trial of EO2463, a potential treatment for indolent non-Hodgkin B-cell lymphomas will be Enterome's second OncoMimics candidate to enter the clinic.

EO2463 is an innovative, off-the-shelf immuno-oncology candidate that combines four Onc lymphocytes-specific lineage markers. The clinical rationale behind targeting these specific lineage ce induce the full depletion of malignant B lymphocytes enriched in iNHL.

OncoMimics are peptides, derived from bacteria present in the gut microbiome, that closely overexpressed tumor-associated antigen (TAA) or lineage-specific markers in solid and liquid tumor oncoMimics are selected based on their ability to trigger the rapid activation of memory T-cells that vexposed to gut bacteria antigens similar to TAAs, and to direct a targeted cell-killing immune respor tumor.

The primary objective of the study is to demonstrate safety, tolerability and efficacy of EO2463 as a mo in combination with standard of care (rituximab and rituximab in combination with lenalidomide) with follicular lymphoma (FL) and marginal zone lymphoma (MZL).

"With EO2463, we are expanding the potential utility of our OncoMimics pipeline into the field of liqu milestone highlights the rapid progress that we are making with this potentially transform immunotherapy approach and builds on the ongoing trials of EO2401 in glioblastoma and in adrenal a extremely excited by our OncoMimics approach as we believe it can be used to target any tumor and has therapeutic potential across all cancers. We look forward to updating you on the progress of the which is expected to start in the second quarter of 2021," said Jan Fagerberg, Chief Medical Officer of

Contacts

Enterome

Marine Perrier
Head of External Communications and Investor Relations
investorrelations@enterome.com

Media Relations

Mark Swallow / Sylvie Berrebi / David Dible Citigate Dewe Rogerson Tel. +44 207 638 9571 enterome@citigatedewerogerson.com

About Enterome

Enterome is a clinical stage biopharmaceutical company developing novel drugs based on its unique ϵ code molecular interactions in the gut microbiome impacting human health. Enterome's success is be unique ability to identify small proteins and peptides ("effectors") from gut bacteria that can deliver a t benefit in humans.

Enterome is leveraging this unique ability to develop two highly promising pipelines of clinical and pre candidates with a focus on cancer, inflammatory and metabolic diseases:

- OncoMimics: highly effective, off-the-shelf immunotherapies against cancers (EO2401, EO2463). E
 Phase 1/2 clinical trials in patients with glioblastoma and adrenal tumors. EO2463, is about to enter
 development for indolent non-Hodgkin B-cell lymphomas.
- EndoMimics: a new generation of biologics targeting inflammatory diseases (EM101) and metabol such as Type 2 diabetes.

These pipelines have been created using Enterome's highly efficient proprietary drug discovery platfor machine learning and lab assays to interrogate and decode the world's largest database of gut bacteri unique source of novel precision drugs.

In addition, Enterome's clinical candidate Sibofimloc (also referred to as TAK-018) is advancing through clinical trials in Crohn's disease. Sibofimloc has been partnered with Takeda globally, with Enterome re significant profit share in the US.

Enterome is headquartered in Paris (France) and is backed by leading venture capital investors.

